Business Terms
Immuneering Partners with Regeneron to Study Combined MEK, PD-1 Inhibitor Therapy in Solid Tumors
Regeneron will supply Libtayo within an ongoing Phase II trial of Immuneering's MEK inhibitor.
Maze Therapeutics Doses First Patient in Phase II APOL1 Inhibitor Kidney Disease Trial
Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.
In Brief This Week: Ocugen, Acrivon, Myriad Genetics, Ariceum, Arbor Biotechnologies
News items for the week of Feb. 3, 2025.
Genomenon, Mirum Pharmaceuticals Partner for Rare Disease Data Sharing
Mirum has tapped Genomenon to produce a "landscape" of CYP27A1 gene variants to improve awareness and diagnosis of cerebrotendinous xanthomatosis.
AstraZeneca Optimistic About Phase III Camizestrant Data in 2025, Reports Strong Q4 Product Growth
Premium
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.